Prostate cancer is the most common type of cancer diagnosed in men and the second most common cause of death from cancer. Initial therapy for patients with androgen-dependent prostate cancer includes hormonal therapy to inhibit the biological effects of androgen receptor (AR) signaling. Recent evidence suggests that the AR is critical for tumor growth in androgen-refractory prostate cancer cells. The ubiquitin proteasome pathway is the primary pathway for protein turnover in all eukaryotic cells that involves the assembly of an ubiquitin chain on a substrate, which then targets the multi-ubiquitinated protein for degradation by the 26S proteasome. A protein complex known as, the SCF (Skp1, Cullin, F-box, and Hrtl/Rbx) ubiquitin ligase specifically targets proteins for ubiquitination and subsequent degradation. We previously demonstrated that a bridging molecule or Protac (Proteolysis Targeting Chimeric molecule) promotes in vitro ubiquitination of a stable protein, Methionine Aminopeptidase-2, and an unstable protein, the estrogen receptor, by SCFbeta-TRCP. We have synthesized a Protac (Protac-3) consisting of the ligand of AR, dihydroxytestosterone (DHT), and the kappa(Balpha-phosphopeptide, which binds SCFbeta-TRCP. Our goal is to develop a new technology in which a Protac links the AR to SCFbeta-TRCP, resulting in ubiquitination and degradation of AR.
The specific aims of this proposal are to: 1) Test the hypothesis that a phosphopeptide-DHT chimera (Protac-3) will link AR to SCFbeta-TRCP, and direct the ubiquitination and degradation of AR in vitro; 2) Test the hypothesis that a phosphopeptide-DHT chimera (Protac-3) will link AR to SCFbeta-TRCP, and increase the ubiquitination and degradation of AR in cells; and 3) Test the hypothesis that small non-peptidic ligands that bind beta-TRCP can be used to generate testosterone-based Protacs that increase AR ubiquitination and degradation. We hypothesize that AR can be targeted to SCFbeta-TRCP resulting in increased turnover of AR in prostate cancer cells. Development of this technology will lead to novel approaches to treat androgen dependent and -independent disease in hopes of improving the survival of men with prostate cancer.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Exploratory/Developmental Grants (R21)
Project #
Application #
Study Section
Drug Discovery and Molecular Pharmacology Study Section (DMP)
Program Officer
Forry, Suzanne L
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of California Los Angeles
Schools of Medicine
Los Angeles
United States
Zip Code
Sakamoto, Kathleen M (2010) Protacs for treatment of cancer. Pediatr Res 67:505-8
Rodriguez-Gonzalez, A; Cyrus, K; Salcius, M et al. (2008) Targeting steroid hormone receptors for ubiquitination and degradation in breast and prostate cancer. Oncogene 27:7201-11
Yang, Zhongan; Jiang, Hong; Zhao, Fang et al. (2007) A highly conserved regulatory element controls hematopoietic expression of GATA-2 in zebrafish. BMC Dev Biol 7:97
Shankar, Deepa B; Li, Junling; Tapang, Paul et al. (2007) ABT-869, a multitargeted receptor tyrosine kinase inhibitor: inhibition of FLT3 phosphorylation and signaling in acute myeloid leukemia. Blood 109:3400-8
Parcells, Bertrand W; Ikeda, Alan K; Simms-Waldrip, Tiffany et al. (2006) FMS-like tyrosine kinase 3 in normal hematopoiesis and acute myeloid leukemia. Stem Cells 24:1174-84
Ikeda, A; Shankar, D B; Watanabe, M et al. (2006) Molecular targets and the treatment of myeloid leukemia. Mol Genet Metab 88:216-24
Federman, Noah; Sakamoto, Kathleen M (2005) The genetic basis of bone marrow failure syndromes in children. Mol Genet Metab 86:100-9
Sakamoto, Kathleen M (2005) Chimeric molecules to target proteins for ubiquitination and degradation. Methods Enzymol 399:833-47
Verma, Rati; Peters, Noel R; D'Onofrio, Mariapina et al. (2004) Ubistatins inhibit proteasome-dependent degradation by binding the ubiquitin chain. Science 306:117-20